
J&J and Yuhan push challenger to AZ’s Tagrisso in Korea with next-phase Rybrevant combo
Yuhan Corp. is wrapping up its chemo-free phase 2 lung cancer trial just as Johnson & Johnson pushes for reimbursement of Rybrevant in Korea -- doubling down on a combo that has already shown an overall survival edge over AstraZeneca’s Tagrisso ( …